Orca Pharmaceuticals, AstraZeneca deal

AstraZeneca will gain access to Orca’s inhibitors of RAR-related orphan receptor C ( RORC; RORgamma). According to the parties, the compounds can be developed to treat autoimmune diseases. AZ has the...